Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077181 · ClinicalTrials.gov registry record · Phase 1
3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT00077181: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00077181 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077181, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side effects and best dose of 3-AP when given with high-dose cytarabine in treating patients with advanced hematologic malignancies
Interventions
- OTHER laboratory biomarker analysis
- DRUG cytarabine
- DRUG triapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2004-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00077181
The ClinicalTrials.gov registry entry for NCT00077181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00077181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00077181 about?
NCT00077181 is a clinical study titled "3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies". Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side effects and best dose of 3-AP when...
What is the current status of trial NCT00077181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2004-01.
What interventions are being tested in trial NCT00077181?
The interventions under investigation include: laboratory biomarker analysis (OTHER), cytarabine (DRUG), triapine (DRUG).
Who is sponsoring clinical trial NCT00077181?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.